Rheumatoid arthritis pathophysiology: Difference between revisions

Jump to navigation Jump to search
 
(37 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
The exact pathogenesis of [disease name] is not fully understood.
[[Rheumatoid arthritis]] is mediated by the combination of a predisposing [[genotype]] along with which [[genetic]] factors, [[Environmental Lung Diseases|environmental]] factors, and [[Microorganisms|microorganisms]] contribute, resulting in the [[inflammation]] and destruction of the [[synovial membrane]]. These factors lead to [[citrullination]] or [[post-translational modifications]], resulting in the production of altered peptides. The altered [[peptides]] bind to [[MHC]] protein with shared [[epitopes]] which further leads to [[antigen]] presentation to [[T-cells]].
[[T-cells]] further stimulate [[B-cells]] and cytokines which results in cartilage damage. [[Mutation]] of [[human leukocyte antigen]] (HLA) genes on [[chromosome]] 6 is involved in pathogenesis of [[rheumatoid arthritis]]. Various conditions associated with [[RA]] include [[vasculitis]], [[uveitis]], [[scleritis]], peripheral [[ulcerative keratitis]],
[[interstitial fibrosis]], pulmonary [[nodules]], [[bronchiolitis obliterans]], organizing [[pneumonia]], [[venous thromboembolism]], [[pericarditis]], [[myocarditis]], [[congestive heart failure]], [[atrial fibrillation]], [[sjogren's syndrome]], and [[felty's syndrome]].


OR
==Pathophysiology==
 
[[Rheumatoid arthritis]] is mediated by the combination of a predisposing [[genotype]] along with [[genetic]] factors, [[Environmental Lung Diseases|environmental]] factors, and [[Microorganisms|microorganisms]], resulting in the [[inflammation]] and destruction of the [[synovial membrane]].
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
 
OR
 
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
 
OR
 
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
 
OR
 
 
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
 
OR


The progression to [disease name] usually involves the [molecular pathway].
'''Various factors involved are''':


OR
'''Environmental factors''':
* Environmental factors lead to repeated activation of [[innate immunity]] at [[mucosal]] surfaces.


The pathophysiology of [disease/malignancy] depends on the histological subtype.
*[[Smoking]] effects the [[genes]] to increase susceptibility up to 20 to 40 fold.
 
**[[Smoking]] causes increased expression of peptidyl arginine deiminase (PAD) in [[alveolar]] [[macrophages]].
==Pathophysiology==
**Peptidyl arginine deiminase converts arginine to [[citrulline]],  the process is known as [[citrullination]], in the airway which further creates neoantigens that can be recognized by the adaptive [[immune system]].<ref name="pmid19479873">{{cite journal |vauthors=Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L |title=Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important |journal=Arthritis Rheum. |volume=60 |issue=6 |pages=1597–603 |date=June 2009 |pmid=19479873 |pmc=2732897 |doi=10.1002/art.24572 |url=}}</ref><ref name="pmid18413445">{{cite journal |vauthors=Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI |title=Smoking increases peptidyl arginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells |journal=Ann. Rheum. Dis. |volume=67 |issue=10 |pages=1488–92 |date=October 2008 |pmid=18413445 |doi=10.1136/ard.2007.075192 |url=}}</ref>
'''Genetic factors:'''
*Genetics factors such as [[human leukocyte antigen]] (HLA)-DR.
*These [[genes]] are involved in inducing [[immune response]], [[matrix]] regulation, and [[inflammation]].<ref name="pmid24072602">{{cite journal |vauthors=Bottini N, Firestein GS |title=Epigenetics in rheumatoid arthritis: a primer for rheumatologists |journal=Curr Rheumatol Rep |volume=15 |issue=11 |pages=372 |date=November 2013 |pmid=24072602 |doi=10.1007/s11926-013-0372-9 |url=}}</ref>
'''Microrganisms:'''
*In [[periodontal disease]], P. gingivalis is commonly found, it also expresses peptidyl arginine deiminases.
*This can lead to [[citrullination]] and thereby promotes anti-citrullinated protein antibodies (ACPA)
*A. actinomycetemcomitans produces a [[toxin]] that increases [[calcium]] influx into [[neutrophils]] which further leads to [[citrullination]] of [[peptides]] and promotes APCA.


===Pathogenesis===
=== '''Pathogenesis''' ===
[[Rheumatoid arthritis]] is mediated by the combination of a predisposing genotype upon which genetic factors, environmental and microorganism resulting in the inflammatory and destruction of the synovial membrane.
*All the above factors lead to [[citrullination]] or [[post-translational modifications]].
'''Environmental factors''': It causes repeated activation of innate immunity at mucosal surfaces.
*The altered [[peptides]] bind to [[MHC]] protein with shared [[epitopes]] which further leads to [[antigen]] presentation to [[T-cells]].
*Smoking interacts with genes to increase susceptibility up to 20- to 40-fold.
*[[T cells]] further stimulate [[B cells]] to produce a range of [[antibodies]] that recognize self-[[proteins]], including [[Rheumatoid factor|rheumatoid]] factors and anti-citrullinated protein antibodies (ACPAs).
**Smoking causes increased expression of peptidyl arginine deiminase (PAD)  in alveolar macrophages.
*[[Fibroblast]]-like synoviocytes, antigen presenting cells (APCs), and [[macrophages]] are activated locally and produce various [[inflammatory]] factors.
**Peptidyl arginine deiminase convert arginine to citrulline called as citrullination in the airway which further creates neoantigens that can be recognized by the adaptive immune system.<ref name="pmid19479873">{{cite journal |vauthors=Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L |title=Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important |journal=Arthritis Rheum. |volume=60 |issue=6 |pages=1597–603 |date=June 2009 |pmid=19479873 |pmc=2732897 |doi=10.1002/art.24572 |url=}}</ref>
*The [[autoimmune]] response causes [[synovial inflammation]] resulting in [[immune complex]] formation and [[complement]] activation, leading to an increase in [[cytokine]] production and [[synovial]] [[vascular]] leakage.
'''Microrganism'''
*[[Cytokine|Cytokines]] lead to [[bone]] and [[cartilage]] destruction.
*In periodontal disease, P. gingivalis is found commonly, it also expresses peptidyl arginine deiminases.
*This can lead to citrullination and thereby promote ACPA.
*A. actinomycetemcomitans produces a toxin that increases calcium influx into neutrophils which further lead to citrullination of peptides and promote APCA.  
**Genetics factors like  class II major histocompatibility complex (MHC), most common human leukocyte antigen (HLA)-DR


==Genetics==
==Genetics==
*[Disease name] is transmitted in [mode of genetic transmission] pattern.
*The development of [[rheumatoid arthritis]] is the result of [[mutation]] of [[human leukocyte antigen]] (HLA) genes on [[chromosome]] 6.<ref name="pmid9608321">{{cite journal |vauthors=Reveille JD |title=The genetic contribution to the pathogenesis of rheumatoid arthritis |journal=Curr Opin Rheumatol |volume=10 |issue=3 |pages=187–200 |date=May 1998 |pmid=9608321 |doi= |url=}}</ref><ref name="pmid21176794">{{cite journal |vauthors=Entezami P, Fox DA, Clapham PJ, Chung KC |title=Historical perspective on the etiology of rheumatoid arthritis |journal=Hand Clin |volume=27 |issue=1 |pages=1–10 |date=February 2011 |pmid=21176794 |pmc=3119866 |doi=10.1016/j.hcl.2010.09.006 |url=}}</ref>
*Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
*The development of [disease name] is the result of multiple genetic mutations.


==Associated Conditions==
==Associated Conditions==
Conditions associated with rheumatoid arthritis include:<ref name="pmid22527950">{{cite journal |vauthors=Deal C |title=Bone loss in rheumatoid arthritis: systemic, periarticular, and focal |journal=Curr Rheumatol Rep |volume=14 |issue=3 |pages=231–7 |date=June 2012 |pmid=22527950 |doi=10.1007/s11926-012-0253-7 |url=}}</ref><ref name="pmid6378209">{{cite journal |vauthors=Halla JT, Koopman WJ, Fallahi S, Oh SJ, Gay RE, Schrohenloher RE |title=Rheumatoid myositis. Clinical and histologic features and possible pathogenesis |journal=Arthritis Rheum. |volume=27 |issue=7 |pages=737–43 |date=July 1984 |pmid=6378209 |doi= |url=}}</ref>
*[[Osteopenia]]
*[[Myositis]]
*[[Vasculitis]]
*[[Uveitis]]
*[[Scleritis]]
*Peripheral [[ulcerative keratitis]]
*[[Interstitial fibrosis]]
*Pulmonary [[nodules]]
*[[Bronchiolitis obliterans]]
*Organizing [[pneumonia]]
*[[Venous thromboembolism]]
*[[Pericarditis]]
*[[Myocarditis]]
*[[Congestive heart failure]]
*[[Atrial fibrillation]]
*[[Sjogren's syndrome]]
*[[Felty's syndrome]]


==Gross Pathology==
==Gross Pathology==
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
On gross pathology of [[rheumatoid arthritis]] the following features may be noticed:<ref name="pmid404905">{{cite journal |vauthors=Resnick D, Niwayama G, Coutts RD |title=Subchondral cysts (geodes) in arthritic disorders: pathologic and radiographic appearance of the hip joint |journal=AJR Am J Roentgenol |volume=128 |issue=5 |pages=799–806 |date=May 1977 |pmid=404905 |doi=10.2214/ajr.128.5.799 |url=}}</ref>
*Irregular surface, seen due to [[synovial]] hyperplasia.
*Subchondral [[cysts]], usually present at the later stage of the disease.


==Microscopic Pathology==
==Microscopic Pathology==
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
On microscopic histopathological analysis:<ref name="pmid14532152">{{cite journal |vauthors=Koch AE |title=Angiogenesis as a target in rheumatoid arthritis |journal=Ann. Rheum. Dis. |volume=62 Suppl 2 |issue= |pages=ii60–7 |date=November 2003 |pmid=14532152 |pmc=1766740 |doi= |url=}}</ref><ref name="pmid9627005">{{cite journal |vauthors=Koch AE |title=Review: angiogenesis: implications for rheumatoid arthritis |journal=Arthritis Rheum. |volume=41 |issue=6 |pages=951–62 |date=June 1998 |pmid=9627005 |doi=10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D |url=}}</ref>
*The earliest finding is the formation of the new synovial [[blood vessel|blood vessels]].
*Hypertrophy of [[synovial]] lining layer and infiltration of [[mononuclear cells]] may be observed.
*Chronic [[inflammation]] with [[lymphocytic]] [[Infiltration (medical)|infiltration]] may be seen.
*There is [[pannus]] formation which consists of fibrovascular tissue or [[Granulation tissue|granulation]] tissue.


==References==
==References==

Latest revision as of 19:54, 23 April 2018

Rheumatoid arthritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rheumatoid arthritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary prevention

Secondary prevention

Future or Investigational Therapies

Case Studies

Case #1

Rheumatoid arthritis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rheumatoid arthritis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Rheumatoid arthritis pathophysiology

CDC on Rheumatoid arthritis pathophysiology

Rheumatoid arthritis pathophysiology in the news

Blogs onRheumatoid arthritis pathophysiology

Directions to Hospitals Treating Rheumatoid arthritis

Risk calculators and risk factors for Rheumatoid arthritis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Rheumatoid arthritis is mediated by the combination of a predisposing genotype along with which genetic factors, environmental factors, and microorganisms contribute, resulting in the inflammation and destruction of the synovial membrane. These factors lead to citrullination or post-translational modifications, resulting in the production of altered peptides. The altered peptides bind to MHC protein with shared epitopes which further leads to antigen presentation to T-cells. T-cells further stimulate B-cells and cytokines which results in cartilage damage. Mutation of human leukocyte antigen (HLA) genes on chromosome 6 is involved in pathogenesis of rheumatoid arthritis. Various conditions associated with RA include vasculitis, uveitis, scleritis, peripheral ulcerative keratitis, interstitial fibrosis, pulmonary nodules, bronchiolitis obliterans, organizing pneumonia, venous thromboembolism, pericarditis, myocarditis, congestive heart failure, atrial fibrillation, sjogren's syndrome, and felty's syndrome.

Pathophysiology

Rheumatoid arthritis is mediated by the combination of a predisposing genotype along with genetic factors, environmental factors, and microorganisms, resulting in the inflammation and destruction of the synovial membrane.

Various factors involved are:

Environmental factors:

Genetic factors:

Microrganisms:

Pathogenesis

Genetics

Associated Conditions

Conditions associated with rheumatoid arthritis include:[6][7]

Gross Pathology

On gross pathology of rheumatoid arthritis the following features may be noticed:[8]

  • Irregular surface, seen due to synovial hyperplasia.
  • Subchondral cysts, usually present at the later stage of the disease.

Microscopic Pathology

On microscopic histopathological analysis:[9][10]

References

  1. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L (June 2009). "Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important". Arthritis Rheum. 60 (6): 1597–603. doi:10.1002/art.24572. PMC 2732897. PMID 19479873.
  2. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI (October 2008). "Smoking increases peptidyl arginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells". Ann. Rheum. Dis. 67 (10): 1488–92. doi:10.1136/ard.2007.075192. PMID 18413445.
  3. Bottini N, Firestein GS (November 2013). "Epigenetics in rheumatoid arthritis: a primer for rheumatologists". Curr Rheumatol Rep. 15 (11): 372. doi:10.1007/s11926-013-0372-9. PMID 24072602.
  4. Reveille JD (May 1998). "The genetic contribution to the pathogenesis of rheumatoid arthritis". Curr Opin Rheumatol. 10 (3): 187–200. PMID 9608321.
  5. Entezami P, Fox DA, Clapham PJ, Chung KC (February 2011). "Historical perspective on the etiology of rheumatoid arthritis". Hand Clin. 27 (1): 1–10. doi:10.1016/j.hcl.2010.09.006. PMC 3119866. PMID 21176794.
  6. Deal C (June 2012). "Bone loss in rheumatoid arthritis: systemic, periarticular, and focal". Curr Rheumatol Rep. 14 (3): 231–7. doi:10.1007/s11926-012-0253-7. PMID 22527950.
  7. Halla JT, Koopman WJ, Fallahi S, Oh SJ, Gay RE, Schrohenloher RE (July 1984). "Rheumatoid myositis. Clinical and histologic features and possible pathogenesis". Arthritis Rheum. 27 (7): 737–43. PMID 6378209.
  8. Resnick D, Niwayama G, Coutts RD (May 1977). "Subchondral cysts (geodes) in arthritic disorders: pathologic and radiographic appearance of the hip joint". AJR Am J Roentgenol. 128 (5): 799–806. doi:10.2214/ajr.128.5.799. PMID 404905.
  9. Koch AE (November 2003). "Angiogenesis as a target in rheumatoid arthritis". Ann. Rheum. Dis. 62 Suppl 2: ii60–7. PMC 1766740. PMID 14532152.
  10. Koch AE (June 1998). "Review: angiogenesis: implications for rheumatoid arthritis". Arthritis Rheum. 41 (6): 951–62. doi:10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D. PMID 9627005.

Template:WH Template:WS